Analyst Targets 200% Upside for This Biopharm

AZRX has been in a downtrend since going public in late 2016

Feb 14, 2019 at 11:01 AM
facebook X logo linkedin

AzurRx BioPharma Inc (NASDAQ:AZRX) is a development stage biopharmaceutical firm whose two pipeline products are being developed to treat exocrine pancreatic insufficiency and c. difficile infections. Optimism around the former drug sparked this morning's bull note from Maxim, with the analyst in coverage initiating coverage on AZRX stock with a "buy" rating and $5 price target -- a 191% premium to last night's close.

This upbeat outlook just echoes the withstanding sentiment seen among the brokerage bunch, with all four covering analysts maintaining a "buy" or better rating. Plus, the average 12-month price target of $7.38 stands at a 321.7% premium to current trading levels.

Looking at the charts, AZRX hasn't traded above $5 since September 2017, and the shares have yet to see the north side of $7.38. Since going public in October 2016, the stock has been trending lower, culminating in a Dec. 27 record low of $1.00.

AzurRx BioPharma took a sharp bounce from here, but was swiftly rejected by its 200-day moving average in late January -- a trendline that's kept a tight lid on the shares over the last six months. The stock has shed 30% since this unsuccessful test, but remains 44.6% higher year-to-date -- up 2% today at $1.75.

azrx stock daily chart feb 14


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI